Surge in Respiratory Medicine Sales Amid Pollution Concerns
Our cities are grappling with a severe air pollution crisis, and the impact is evident in rising medical expenses. Sales of respiratory medications, including anti-allergics and anti-asthma treatments, soared to over Rs 1,950 crore in December 2025, marking the highest monthly sales on record. This increase, which represents a 10% rise from December 2024 and an 18% jump from December 2023, highlights a troubling trend in pollution-related health issues. The data, compiled by market research firm Pharmarack, reveals that respiratory therapy sales reached Rs 5,620 crore in the October to December quarter, reflecting a 14% year-on-year increase compared to 2024.
Surge in Respiratory Medication Sales
The alarming rise in respiratory medication sales underscores the growing health crisis linked to air pollution. In December 2025, sales surpassed Rs 1,950 crore, the highest monthly figure ever recorded. This increase is not an isolated incident; it marks a consistent upward trend over the past few years. The sales figures for the October to December quarter, a period notorious for heightened pollution levels, also saw a significant increase, with a 14% rise compared to the same quarter in 2024 and an 8% increase from 2023. Notably, anti-asthma and chronic obstructive pulmonary disease (COPD) medications accounted for nearly Rs 3,500 crore of the total sales, indicating a growing reliance on these therapies as air quality deteriorates.
Impact of Air Pollution on Health
Medical experts warn that exposure to air pollution can exacerbate respiratory conditions, leading to serious health issues such as asthma and chronic obstructive pulmonary disease. Amitabh Malik, head of the ENT department at Paras Health in Gurgaon, noted that the rise in suspended particles in the air correlates with a 60% increase in patients suffering from allergic rhinitis and bronchitis. He emphasized the importance of using masks and air purifiers, particularly for vulnerable individuals. The treatment landscape is increasingly dominated by steroid inhalers and anti-allergics, which form the cornerstone of managing these conditions during the winter months.
Seasonal Trends in Medication Demand
The winter months typically see a spike in upper respiratory infections, leading to increased demand for related medications. A representative from GSK Pharma India highlighted that the period from October to February coincides with a seasonal rise in these infections, exacerbated by poor air quality. This trend is not limited to one region; data indicates that both northern and southern regions of India are experiencing similar increases in medication sales. Pharmarack’s recent update noted that multiple areas recorded double-digit month-on-month growth, suggesting that the health impacts of winter air pollution are becoming a persistent public health concern rather than a mere seasonal fluctuation.
Broader Implications for Public Health
The escalating sales of respiratory medications reflect a broader public health crisis driven by air pollution. As cities continue to struggle with deteriorating air quality, the implications for public health are significant. The domestic pharmaceutical market, estimated at Rs 2.4 lakh crore annually, is increasingly influenced by the demand for respiratory therapies. The data indicates that the health challenges posed by air pollution are not only affecting individual health but also straining healthcare resources. As the trend continues, it is crucial for policymakers and health authorities to address the underlying causes of air pollution to mitigate its impact on public health.
Observer Voice is the one stop site for National, International news, Sports, Editor’s Choice, Art/culture contents, Quotes and much more. We also cover historical contents. Historical contents includes World History, Indian History, and what happened today. The website also covers Entertainment across the India and World.
Follow Us on Twitter, Instagram, Facebook, & LinkedIn
